Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : genelabs(gnlb) -- Ignore unavailable to you. Want to Upgrade?

To: Toni Wheeler who wrote (177)	2/13/2000 9:43:00 AM
From: JH	Read Replies (2) \| Respond to of 233

Thanks, Toni, for your response. I was one of the early investors who participated in Genelabs' Regulation-S secondary stock offering (for foreign investors) about four years ago. My cost basis was around $1. I sold enough shares to recoup my entire investment in a few weeks when the stock traded up to around $3, and kept the rest in "deep freeze" for a long, long, time. The recent run-up represents the belated "payoff". The tough part now, is deciding when to SELL ! I am inclined to put in sell-stops, perhaps 25% at $13-1/4, 25% at $13, 25% at $12, and the final piece at $11-1/2. My reasoning is that the stock has priced in a great deal of the optimism surrounding the conference already, and that there is a good possibility of a retracement down to $10 on the combination of profit-taking and market correction. Otherwise, if the stock wants to climb higher, I will simply adjust my stops appropriately higher.